TLTFF Stock Recent News Theralase Technologi (TLTFF) 0.3340 11/14/2014

New Post Public Reply Private Reply Replies (0) Message Board

Nov 15, 2014 at 12:25 AM

Theralase Technologi (TLTFF) 0.3340 $TLTFF

Theralase Further Validates Anti-Cancer Memory Response
ACCESSWIRE - Wed Nov 12, 6:01AM CST
Toronto, Ontario / ACCESSWIRE / November 12, 2014 / Theralase Technologies Inc. ("Theralase"

(TSXV: TLT) (TLTFF: OTCBB) announced today that in new preclinical research, conducted at Princess Margaret Cancer Centre, University Health Network ("UHN"

, that it has further validated its Photo Dynamic Compound's ("PDCs"

ability to destroy a primary host tumour and even more importantly render the animal immune to a repeated exposure of the same cancer.
TLT.VN: 0.370 (+0.010)

Theralase Presents Latest Research on Destruction of Cancer and Bacteria at International Conference
ACCESSWIRE - Thu Oct 16, 6:09AM CDT
Toronto, Ontario - October 16, 2014 -Theralase Technologies Inc. ("Theralase(R)"

(TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has presented its latest research on the success of its Photo Dynamic Compounds ("PDCs"

in the destruction of cancer and bacteria. This research was presented at the 10th International Symposium on Photodynamic Therapy and Photodiagnosis in Clinical Practice, taking place in Brixen, Italy from October 14 to 18, 2014.
TLT.VN: 0.370 (+0.010)

Theralase Partners with SAFC in Manufacture of Anti-Cancer Drugs
ACCESSWIRE - Tue Oct 07, 6:08AM CDT
Toronto, Ontario / ACCESSWIRE / October 7, 2014 / Theralase Technologies Inc. ("Theralase(R)"

(TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has collaborated with Sigma-Aldrich Corporation's (NASDAQ: SIAL) custom manufacturing services business unit SAFC(R) Commercial , in the manufacture of the Photo Dynamic Compounds ("PDCs"

being developed by Theralase for the destruction of cancer.
SIAL: 135.58 (+0.05), TLT.VN: 0.370 (+0.010)

Theralase Files Voluntary Annual Information Form
ACCESSWIRE - Wed Sep 24, 6:01AM CDT
Toronto, Ontario / ACCESSWIRE / September 24, 2014 / Theralase Technologies Inc. ("Theralase(R)"

(TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has filed a voluntary Annual Information Form ("AIF"

as part of its corporate strategy to become eligible for the registration of a base shelf prospectus as this term is defined in National Instruments 44-101 Short Form Prospectus Distributions and 44-102 Shelf Distributions.
TLT.VN: 0.370 (+0.010)

Theralase Partners with Montreal's JSS Medical Research to Bring Innovative Bladder Cancer Treatment to Market
ACCESSWIRE - Thu Sep 11, 6:01AM CDT
Toronto, Ontario / ACCESSWIRE / September 11, 2014 / To take advantage of the vastly improved business climate in Quebec, Theralase Technologies Inc. ("Theralase"

(TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it is partnering with JSS Medical Research Inc. ("JSS"

, a Montreal based Contract Research Organization ("CRO"

, to consult and provide guidance in the completion of a FDA / Health Canada Phase I/IIa clinical study. The clinical study planned for early 2015 will evaluate the safety and efficacy of Theralase's innovative Photo Dynamic Therapy ("PDT"

platform in the destruction of bladder cancer. Theralase anticipates executing further agreements in the Quebec biotech sector worth several million dollars over the next 12 to 18 months.
TLT.VN: 0.370 (+0.010)

Theralase Launches Multi Wavelength Laser for Cancer Destruction
ACCESSWIRE - Tue Sep 09, 6:04AM CDT
Toronto, Ontario / ACCESSWIRE / September 9, 2014 / Theralase Technologies Inc. ("Theralase"

(TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has successfully launched its TLC-3000 multi wavelength laser system capable of activating its patented and patent pending Photo Dynamic Compounds (PDCs) for the destruction of cancer in an preclinical environment. This is the first commercial system on the market capable of effectively activating a 96 well plate of cancer cells with wavelengths in the visible to Near Infrared (NIR) spectrum using programmable energy levels. Intellectual protection for this system was recently applied for under a pending US patent.
TLT.VN: 0.370 (+0.010)

Theralase Releases 2Q2014 Financials
ACCESSWIRE - Fri Aug 29, 6:06AM CDT
Toronto, Ontario / ACCESSWIRE / August 29, 2014 / Theralase Technologies Inc. ("Theralase"

(TLT: TSXV) (TLTFF: OTC Link) released its second quarter 2014 financial results today, demonstrating a slight increase in revenue for the three month period ended June 30, 2014, edging up 1% year over year, while successfully advancing its patented next generation therapeutic laser and cancer destruction technologies.

Theralase Advances Intellectual Property of Anti-Cancer Technology
ACCESSWIRE - Thu Jul 17, 6:04AM CDT
Toronto, Ontario / ACCESSWIRE / July 17, 2014 / Theralase Technologies Inc. ("Theralase"

(TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has applied for a US patent for a multi-wavelength laser light source that is capable of safely and effectively activating its patented and patent pending Photo Dynamic Compounds (PDCs) in the destruction of cancer at various tissue depths.
TLT.VN: 0.370 (+0.010)

Theralase Grants Stock Options
ACCESSWIRE - Wed Jul 16, 6:02AM CDT
Toronto, Ontario / ACCESSWIRE / July 16, 2014 / Theralase Technologies Inc. ("Theralase"

(TSXV: TLT) (TLTFF: OTC Link(R)) announced effective today that it has granted an aggregate of 1,800,000 stock options to directors and officers at an exercise price of $CAN 0.50 vesting over three years and expiring five years from date of issue.
TLT.VN: 0.370 (+0.010)

Theralase Technologies Treats 1 Million Patients, CEO Clip Video
Newsfile Corp - Mon Jun 30, 4:26PM CDT
full story)
TLT.VN: 0.370 (+0.010)

BTV Reports on Roche, Sorrento Therapeutics Takes on a Goliath, Plus Biotech Up-and-Comers
Marketwire - Thu Jun 26, 5:01AM CDT
BTV-Business Television goes on location to bring investors expert analyst commentary and stories on emerging companies for their portfolio.
SRNE: 4.23 (+0.02), CGIX: 6.33 (-0.25)

Theralase Releases Peer-Reviewed Research on Anti-Cancer Memory Response and Destruction of Cancerous Cells
ACCESSWIRE - Tue Jun 24, 6:04AM CDT
Toronto, Ontario / ACCESSWIRE / June 24, 2014 / Theralase Technologies Inc. ("Theralase"

(TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has publicly released two significant peer-reviewed research papers concerning the destruction of cancer.
TLT.VN: 0.370 (+0.010)

Theralase Partners with University of Toledo in Cancer Research
ACCESSWIRE - Wed Jun 18, 6:03AM CDT
Toronto, Ontario / ACCESSWIRE / June 18, 2014 / Theralase Technologies Inc. ("Theralase"

(TSXV: TLT) (TLTFF: OTC Pink(R)) announced today that it has executed an agreement with the University of Toledo to conduct preclinical research into the safety and effectiveness of Theralase's Photo Dynamic Compounds (PDCs) in the destruction of bladder cancer in a rat model. The study is entitled, "The use of novel Photo Dynamic Therapy (PDT) in a rat bladder tumor model."
TLT.VN: 0.370 (+0.010)

Theralase's Cancer Technology Demonstrates Vaccine-Like Properties
ACCESSWIRE - Mon Jun 16, 7:04AM CDT
Whitefish, MT / June 16, 2014 / Conventional cancer treatment involves surgically removing cancerous tumors and then killing the remaining cells with toxic chemotherapy drugs. Unfortunately, these approaches involve invasive surgeries and the indiscriminant killing of cells that lead to the immune system being compromised. The success rates for these treatments, particularly in later stage cancers, also leave a lot to be desired.
INO: 11.00 (-0.01), GALE: 1.87 (-0.01), TLT.VN: 0.370 (+0.010), IMUC: 0.65 (+0.08)

Theralase Stock Upgraded on US OTC Market
ACCESSWIRE - Thu Jun 12, 6:05AM CDT
Toronto, Ontario / ACCESSWIRE / June 12, 2014 / Theralase Technologies Inc. ("Theralase"

(TSXV: TLT) (TLTFF: OTC Link(R)) announced that effective June 3, 2014, its common shares, which trade in the United States Over The Counter (OTC) market under the trading symbol TLTFF, have been upgraded on a venue change from the Grey Market to the OTC Link Market.
TLT.VN: 0.370 (+0.010)

Theralase Developing Next Generation Medical Lasers
ACCESSWIRE - Tue Mar 25, 6:13AM CDT
Toronto, Ontario / ACCESSWIRE / March 25, 2014 / Theralase Technologies Inc. (TSXV: TLT) (TLTFF: OTCBB) announced today the expansion of its engineering team to develop and commercialize its next generation of smart medical laser technologies. This highly trained engineering team will be instrumental in developing Theralase products to eliminate pain and heal tissue, a $100 Billion industry in the US and to destroy cancer, a $77 Billion industry in the US.
TLT.VN: 0.370 (+0.010)

Theralase CEO to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM
Marketwire - Wed Mar 12, 6:05AM CDT
Theralase Technologies Inc. (OTCBB: TLTFF) (TSX VENTURE: TLT) sells patented, superpulsed laser technology to healthcare practitioners to heal damaged tissue and eliminate pain. Theralase is also developing the next generation cancer treatment combining patented light activated compounds with laser technology to hunt down and destroy cancer.
TLT.VN: 0.370 (+0.010)

Theralase Releases Financial Results for Second Quarter 2013
ACCESSWIRE - Fri Aug 30, 6:00AM CDT
Toronto, Ontario - August, 30, 2013 Theralase Technologies Inc. (TSXV: TLT) released its second quarter 2013 financial results today, demonstrating an increase in profitability by 27% year over year, while successfully advancing its patented therapeutic laser and cancer destruction technologies.
TLT.VN: 0.370 (+0.010)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Breeze Airways Secures $228M for Fleet Expansion

Breeze Airways and AIP's Milestone Deal Just as the ink is drying on the balance sheets, Breeze Airways is busy making significant moves in the aviation game. Partnering with AIP Capital, they just locked in a $228 million secured debt facility to grab six new Airbus A220-300 aircraft. Now, that’s how you stake your claim in the market. What we’ve got here isn’t...

PJM Prepares to Tackle Winter Power Demands

Eyeing the Season Ahead The chill in the air isn't just meteorological; there's a business note to notice every winter in PJM's sprawling territory. With power supplies robust yet stretched thin, PJM is bracing to navigate another demanding cold season. They’ve announced they have 182,426 MW of operational capacity nipping at the heels of a projected peak demand of...

Democracy's Living History at Long Island University

America’s democracy is getting its moment in the spotlight over at Long Island University, and it's more than just statues and old papers. This exhibition, "The Presidency & Promise of America: A More Perfect Union," unpacked on October 28, throws open a window into the U.S.'s democratic journey from its scrappy beginnings to today’s hot zones of political debate. And...

Yesway's Festive Campaign Drives Holiday Sales Surge

A Holiday Extravaganza in Convenience Retail Here's the deal: Yesway's pulling out all the stops this holiday season, and they're not just offering cheap hotdogs or knocking a nickel off the gas. They're diving into some fiery New Mexico-inspired festivities with their latest campaign, “Red or Green…or Christmas?” It's like a candy cane made of salsas—just in time...

Understanding Your Home's Water Pressure Issues

Why Is My Water Pressure Acting Up? We've all been there—turn on the tap or jump in the shower, and instead of a steady stream, you're met with a dribble. Frustrating, right? You might rush to blame the utility company or maybe the unsettling idea you live in a haunted house. But let's knock some sense into this situation: it's usually something closer to home. Spotting...

Stoneleigh Celebrates Forbes VERIFIED Luxury Praise

Stoneleigh's Milestone in Luxury Living There are times when a luxury residence transcends mere bricks and mortar, and lands squarely in the realm of a lavish lifestyle. That's exactly what Residences at the Stoneleigh in Dallas aims to provide. Recently, the property snagged the coveted VERIFIED™ Luxury Residences designation from Forbes Travel Guide. Now, whether...

Hyster-Yale Navigates a Rocky Q3 2026 Recovery

Imagine Hyster-Yale like a battered ship in a stormy market, steering its way towards stability with a few promising signals on the horizon. Despite a 15% dip in revenue compared to last year, they're celebrating a hefty boost in bookings—up 45% from the rough waters of Q2 2025. It's a mixed bag of tales from the latest quarterly results that might have you scratching...

Compass Confronts Legal Storm After 28% Stock Plunge

An Unwelcome Surprise for Compass Investors Ah, there's nothing quite like the bitter taste of a stock taking a nosedive, is there? For folks holding shares of Compass, Inc. (NYSE: COMP), that bitter pill came with a goose egg of a 28% drop. Now, they're in the thick of a class action lawsuit alleging securities fraud. If you're in on this, grab a coffee. There's plenty...

Birth Registration Revolution: OSIA Interoperability Demo

Bringing Birth Registration into the 21st Century Alright, let's cut through the fog. If you ask most folks about their birth certificates, you'd hear tales of tattered paper and government office runs. What if I told you this vital piece of paper could be reborn altogether? That's what the Secure Identity Alliance is up to with their OSIA Live Interoperability Demo at...

Coronation Securities: Pioneering Digital Brokerage in Nigeria

Coronation Securities: A Digital Revolution Ah, Nigerian financial markets have found themselves a trailblazer, folks. Meet Coronation Securities Limited, recently crowned the 'Fastest Growing Digital Brokerage Platform – Nigeria' at the 2026 Global Brand Awards. Now, that's a nod from Global Brands Magazine worth sitting up for. Turning the Tide with Tech In an...